Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1 Dose Ranging Study to Assess the Safety, Reactogenicity, and Immunogenicity of PepGNP-COVID19, a Synthetic Nanoparticle-based, T Cell Priming Peptide Vaccine Against SARS-CoV-2 As a Booster Dose

NCT07183709 is registered in ClinicalTrials.gov with National Institute of Allergy and Infectious Diseases (NIAID) as lead sponsor.

NCT NCT07183709
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07183709 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1 Dose Ranging Study to Assess the Safety, Reactogenicity, and Immunogenicity of PepGNP-COVID19, a Synthetic Nanoparticle-based, T Cell Priming Peptide Vaccine Against SARS-CoV-2 As a Booster Dose
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Phase
Phase 1
Overall status
Active, not recruiting
Start date
February 2, 2026
Completion date
October 18, 2026
Enrollment
60 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19